EFSA says Arla’s protein hydrolysate meets new EU requirement for infant formula, follow-on formula
On February 22, 2022, a new regulation kicked into effect in the EU for infant formulas and follow-on formulas containing protein hydrolysates, requiring companies to submit dossiers on their ingredients so that EFSA can evaluate their safety and suitability for use in these products.
The European Food Safety Authority (EFSA) published a positive opinion acknowledging that Arla Foods Ingredients’ Peptigen IF-3080 protein hydrolysate ingredient is safe for use in infant formulas and follow-on formulas in the EU.
On February 22, 2022, a new regulation kicked into effect in the EU for infant formulas and follow-on formulas containing protein hydrolysates, requiring companies to submit dossiers on their ingredients so that EFSA can evaluate their safety and suitability for use in these products. Ingredients not approved cannot be sold in the market in these products.
Arla Foods Ingredients’ Peptigen IF-3080 is “one of only a few milk protein hydrolysate ingredients to receive a positive EFSA opinion to date,” the company stated in a March 2022 press release.
“We are delighted by this opinion, which supports our reputation for having the industry’s highest levels of quality, innovation, and food safety,” stated Anders Steen Jørgensen, head of SBU Pediatric, Arla Foods Ingredients, in the press release.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
